Clinical trial

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women…

NCT00002628 · St. Louis University, Other · Unknown status

Key facts

NCT number NCT00002628
Title Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer
Official title PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO THE HIGH DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL SUPPORT IN PATIENTS WITH BREAST CANCER
Lead sponsor St. Louis University, Other
Status Unknown status
Phase Phase 1/Phase 2
Study type Interventional
Conditions Breast Cancer
Intervention type Biological, Drug, Procedure
Interventions filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Enrollment 50
Start date Nov 1, 1994
First posted Aug 31, 2004
Last update posted Jan 10, 2014
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies